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Table
G. CSF Pilot Interim Analysis
No G. CSF
Median (Days)
G CSF
Control (Days)
Autologous (7 Cases, 10 Controls)
LOS 15 12
Neutrophil Engraftment 12 10
Allogeneic MAC (BM & PBPC)
(9 Cases, 9 Controls)
LOS 22 17
Neutrophil Engraftment 22 12
Allogeneic RIC (PBPC) (10 Cases,
10 Controls)
LOS 19 17
Neutrophil Engraftment 14 13
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perspective.
Conclusion: While our 30 day readmission rate has
decreased from 34.6 in 2009 to current rate of 23.5 (See
Figure), we still have work to do. The initial reduction cannot
be attributed to any particular effort(s) and we will continue
to be diligent and innovative in this endeavor. Some
readmissions are not preventable and fevers are a big
barrier. In the near future we hope to create a working
group with other institutions, focus on the patients who
are readmitted frequently, and develop criteria to deﬁne
what a true preventable readmission is.
122
Building a Quality Plan for a Blood and Marrow
Transplant Program: Quality Framework and Indicator
Development
Emma Mauti 1, Roxanne MacAskill 1, Christine Chen 1,
Matthew Seftel 2, Vishal Kukreti 1. 1 Princess Margaret Cancer
Centre, Toronto, ON, Canada; 2 Allogeneic Blood and Marrow
Transplant Program, Princess Margaret Cancer Center,
University of Toronto, Toronto, ON, Canada
Introduction: Quality of care is a priority among patients,
providers, and accreditors in blood and marrow trans-
plantation (BMT), and has resulted in the need to develop
quality management systems. BMT programs can apply
quality frameworks such as the Model for Improvement,
which guide programs to set quality goals, and to develop
quality measurement and reporting strategies to ensure
progress toward those goals. We report on the systematic,
end-user-informed development of a set of quality in-
dicators, to be monitored and reported on in the context of a
quality framework at the Princess Margaret Cancer Centre
BMT program.
Methods: This involved three phases: 1) Evidence Review
(database and grey literature search for quality indicators
used in BMT); 2) Modiﬁed Delphi process, inwhich identiﬁed
indicator concepts were discussed to generate a list of broad
clinical categories, then prioritized via a staff survey; and 3)
investigation of the published literature for data standards
for these indicators.
Results: Evidence review generated 214 indicators, which
were categorized as Clinical (n¼139), Management-level
(n¼40), or Hospital-wide (n¼35). Only the Clinical in-
dicators were deemed meaningful for staff prioritization.
By merging like concepts, the 139 indicators were reduced
to 22 for inclusion in the prioritization exercise. Prioriti-
zation was achieved through an online survey sent to 152
clinical BMT staff. Respondents ranked indicators based on
their perceived clinical value as quality measures. Re-
spondents ranked “Survival” and “Treatment-related mor-
tality” most frequently in their top 3 choices. However, a
low survey response rate (35 of 152, or 23%) suggested a
lack of staff awareness of quality measurement, and a need
to coordinate staff education and creation of a quality
improvement culture to ensure success of such initiatives
in the future. Next, Management-level indicators were
pared down through discussion and consensus, generating
12 indicators to be developed for future reporting. The
Hospital-wide indicators, which were non-BMT-speciﬁc
but could be adapted for use in BMT quality measurement,
were mapped to corresponding Management-level and
Clinical indicators. Their existing measurement structures
may be useful in developing measurement strategies for
our BMT-speciﬁc quality indicators. Finally, workingtoward eventual implementation, all indicators were
assessed for any data standards mentioned in the litera-
ture. Our ﬁndings revealed a paucity of published data
standards for BMT quality indicators, highlighting a need
for more research in this ﬁeld.
Conclusions: Quality indicator development in BMT can be
undertaken systematically, but requires a concerted effort
from staff engagement to informatics infrastructure.
Currently, this area is challenged by a lack of published
development standards and implementation studies.123
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Background: The use of granulocyte colony stimulating
factor (G-CSF) to promote engraftment after hematopoietic
cell transplantation (HCT) remains controversial. Random-
ized controlled trials that showed a shorter duration of
neutropenia after G-CSF in autologous (auto) HCT recipients
were performed in an era when present supportive care
resources were not available. The use of G-CSF after allo-
geneic (allo) HCT is not established by randomized trials
and there is a concern that it may be associated with an
increased risk of graft-versus-host disease. G-CSF is a costly
drug and excluding its routine use may translate into sig-
niﬁcant cost savings for a transplant program. All inpatients
transplanted routinely receive G-CSF 480 mcg/day starting
day +5. We conducted a pilot study to evaluate if G-CSF
post-HCT could be safely omitted after autologous and
allogeneic HCT.
Methods: 2013 data was used as benchmarks for neutrophil
engraftment and hospital length of stay (LOS), calculated
from day 0. Three separate pilots were conducted for auto
HCT, myeloablative (MAC) allo and reduced-intensity (RIC)
allo HCT recipients. Eligibility criteria included sufﬁcient cell
dose for the product to be infused (PBSC 5.0 x106 CD34+
cells/kg for autos,2.0 x106/kg for allos or BM2.0x108 TNC/
kg). G-CSF was not administered prophylactically, but could
be given in clinical scenarios such as prolonged febrile
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Accrual target was 20 patients for each group with a planned
interim analysis afterw10 patients. For each pilot patient, a
control was randomly selected from 2013; controls were
matched by age, graft source, diagnosis and cell dose.
Implementation of the pilot was the effort of a multi-disci-
plinary team including physicians, mid-level providers,
nurses, clinical pharmacists, data and quality assurance
personnel.
Findings: For the auto and allo MAC groups, interim analysis
revealed that omission of G-CSF led to longer LOS and longer
time to neutrophil engraftment (see Table). The interim
analysis of the allo RIC group appears to be comparable for
the length of stay and neutrophil engraftment.
Discussion: Any cost savings of not using G-CSF are likely to
be offset by the longer duration of post-transplant hospital-
ization and possible increased risks due to longer periods of
neutropenia. Based on our ﬁndings, the pilot has been dis-
continued for auto and allo MAC transplants, where we will
continue to use G-CSF starting on Day +5 to promote
engraftment. This pilot will accrue the planned 20 patients
for allogeneic RIC patients before a ﬁnal analysis is per-
formed.PHARMACY
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Background: Methotrexate (MTX) is routinely utilized for
prophylaxis of graft versus host disease (GVHD). MTX may
contribute to mucositis and delayed engraftment. Severe
mucositis results in MTX dose reduction, holding day +6 and/
or day + 11, addition of folinic acid (FA), or the use of dexa-
methasone. Delivery of day +11 MTX has been reported to be
important in reducing the risk of aGVHD. FA administration
after MTX doses has been shown to reduce MTX toxicity. In
an effort to reduce the incidence of mucositis to improve the
likelihood of administering day +11 MTX and to provide a
consistent treatment guideline, the Hematopoietic Cell
Transplant (HCT) program director enlisted the help of the
HCT pharmacist to review the data and recommend
guidelines.
Methods: A review of the literature for post-MTX FA use was
performed and presented at an HCT program education
session. FA dosing, time of initiation post MTX, schedule and
number of doses were discussed. The HCT providers agreed
to follow the HCT pharmacist recommendation of FA 10mg/
m2 IV every 6 hours x 3 doses starting 12 hours after each
MTX dose (day +1, +3, +6 and +11) with myeloablative (MA)
conditioning regimens. All patients received tacrolimus. Data
was retrospectively collected in 2013 after the FA guideline
was adopted and compared to consecutive patients receiving
MA regimens from a control group in 2012. The primary
endpoint was administration of full dose day +11 MTX. Sec-ondary endpoints were rates of aGVHD, cGVHD, total
parenteral nutrition (TPN) use, patient controlled analgesia
(PCA) use, transplant-related mortality (TRM), relapse and
overall survival (OS).
Results: The FA group consisted of 27 patients while there
were 31 in the control. Patients in the FA group were more
likely to receive full dose day +11 MTX as compared to con-
trol, 85.2% vs 48.4% (p¼0.0025) and were less likely to
require PCA, 63% vs. 87.1% (p¼0.03). There was no signiﬁcant
difference in rates of TPN use (48.2% vs. 58.1%), grade II-IV
aGVHD at day 100 (50.4% vs. 30.5%), cGVHD (19.9% vs. 27.7%),
cumulative incidence of relapse (10.8% vs. 8.6%), TRM at 1
year (13.1% vs.19.5%) and OS at 1 year (77.9% vs. 75.9%) for the
FA group and control, with a median follow-up of 465 days
and 670 days, respectively.
Discussion: Patients experienced less mucositis and were
more likely to receive full dose day + 11 MTX after
implementation of the FA guideline. This was also sup-
ported by a statistically signiﬁcant decrease in PCA use.
Other endpoints trended in a favorable direction, but did
not reach statistical signiﬁcance. The development and
utilization of the program guideline improved consistency
of care, improved staff satisfaction and decreased patient
discomfort. HCT pharmacists play an important role in the
review of literature and development of program guide-
lines.125
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Background: Anti-thymocyte globulin (ATG) is often
incorporated into allogeneic stem cell transplant (alloHCT)
conditioning regimens to prevent graft-versus-host disease
(GVHD). Literature regarding the effect of ATG on outcomes
is mixed; some data suggests an improvement in GVHD
control with ATG use, but other data shows a reduction in
overall survival, particularly in the reduced intensity
setting. This study evaluates the impact of ATG on infection,
GVHD, relapse, and mortality rates in adult alloHCT
patients.
Methods: A retrospective review of 250 adult alloHCT
patients at our institution (125 unrelated/mismatched
donor recipients received ATG, 125 matched related do-
nors did not) between 2006 and 2013 was performed.
Charts were reviewed for ATG use, demographics, in-
fections (bacterial, viral, fungal), infection source, GVHD,
day-180 relapse, and day-180 mortality. The primary
endpoint was infection rate; secondary endpoints included
mortality and GVHD.
Results: Factors with signiﬁcant impact on infection inci-
dence were conditioning type (Myeloablative (MAC) >
Reduced Intensity (RIC), p¼0.0105), age (p¼0.0245), and
use of ATG (p¼0.0185). MAC was associated with greater
